Page 46 - Binder2

Because the current approach isn’t just unsustainable—it’s
unfair.

The Path Forward

This book is not just an indictment. It’s a roadmap. In the
chapters ahead, we’ll trace the biological roots of immune
rejection. We’ll explore the historical missteps that led us
here. We’ll examine the structural flaws in clinical trials,
regulatory oversight, and commercial incentives. And most
importantly, we’ll spotlight the scientific advances
already reshaping the landscape of immune-compatible
therapies.

You’ll meet the scientists pioneering oral biologics and
tolerogenic adjuvants. The companies embracing plant-
based systems. The immunologists rethinking how
tolerance is measured—and how it can be built from the
ground up.

This is more than a scientific shift. It’s a cultural one. It
demands new frameworks, new questions, and new
standards for how we evaluate, deliver, and discuss
biologic drugs.

Because biologics aren’t going away.
They are the future of medicine.
But if we don’t redesign them for immune harmony, that
future will be brittle, costly, and fragmented.

The immune rebellion has already begun.
Now we learn how to win it—with science, with humility,
and with the courage to ask better questions than the ones
we started with.

44